asthma or COPD with bronchospasm
Respiratory · 2019–2019
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| salbutamol Relief of bronchospasm in patients with asthma or COPD, and for acute prophylaxis against exercise-induced asthma and other stimuli known to induce… | Nov 2019 | Recommended with restriction | 7 individuals Asthma Australia · Lung Foundation |
Who spoke
Asthma Australia · Lung Foundation
What the PBS pays
$62M in government benefit over 2024–25, across 2,957,653 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| salbutamol | $62.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.